AtheroNova Completes Successful Pre-IND Meeting with FDA on AHRO-001 Sacramento Bee AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AHRO-001 uses certain natural ...
Everist Genomics Announces Acquisition of Angiologix, Inc. MarketWatch (press release) Clinical syndromes such as stable and unstable angina, acute myocardial infarction, claudication, and stroke relate, in part, to a loss of endothelial control of vascular tone, thrombosis, and the composition of the vascular wall. ...